Kalaris Therapeutics Inc.
Filing:
8-K
Filed On:
03/18/25  5:04 PM  EDT
Share
Printing Unavailable
PDF Unavailable
No Tables to Download
Compare Unavailable
Exhibits
8-K
from 8-K 18 pages 8-K
03/18/25
EX-3.1
from 8-K 2 pages Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation of Allovir, Inc
03/18/25
EX-3.2
from 8-K 5 pages Restated Certificate of Incorporation of Kalaris Therapeutics, Inc. (Originally Incorporated Under the Delaware General Corporation Law (The Dgcl”) on September 17, 2018 Under the Name Viracyte, Inc.)
03/18/25
EX-3.3
from 8-K 15 pages Amended and Restated By-Laws of Kalaris Therapeutics, Inc
03/18/25
EX-10.3
from 8-K 11 pages December 31, 2024 Matthew Feinsod, MD [***] [***] [***] [***] Re: Offer of Employment by Kalaris Therapeutics, Inc. Dear Matt: I Am Very Pleased to Confirm Our Offer to You of Employment With Kalaris Therapeutics, Inc. (The “Company”). the Terms of Our Offer and the Benefits Currently Provided by the Company Are as Follows
03/18/25
EX-10.4
from 8-K 53 pages Napoco, Inc. 2019 Equity Incentive Plan as Adopted on September 30, 2019
03/18/25
EX-10.5
from 8-K 42 pages Kalaris Therapeutics, Inc. 2020 Stock Option and Grant Plan, as Amended
03/18/25
EX-10.6
from 8-K 11 pages Kalaris Therapeutics, Inc. [Form Of] Director Indemnification Agreement
03/18/25
EX-10.7
from 8-K 10 pages Kalaris Therapeutics, Inc. [Form Of] Officer Indemnification Agreement
03/18/25
EX-10.8
from 8-K 73 pages Lease Between the Connell Company Landlord and Kalaris Therapeutics, Inc. Tenant 400 Connell Drive
03/18/25
EX-21.1
from 8-K 1 page Subsidiaries of the registrant
03/18/25
EX-23.1
from 8-K 1 page Consent of expert or counsel
03/18/25
EX-99.1
from 8-K 4 pages Kalaris Announces Closing of Merger With AlloVir
03/18/25
EX-99.2
from 8-K 60 pages Press releases and additional exhibits
03/18/25
EX-99.3
from 8-K 44 pages Press releases and additional exhibits
03/18/25
EX-99.4
from 8-K 17 pages Kalaris’ Management’s Discussion and Analysis of Financial Condition and Results of Operations
03/18/25
EX-99.5
from 8-K 32 pages Kalaris Therapeutics, Inc
03/18/25
EX-99.6
from 8-K 13 pages Unaudited Pro Forma Condensed Combined Financial Data
03/18/25
Graphics & Data Files
GRAPHIC
from 8-K g925335d106.jpg
03/18/25
GRAPHIC
from 8-K g925335d107.jpg
03/18/25
GRAPHIC
from 8-K g925335d108.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224732835.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224733225.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224733420.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224733615.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224733887.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224734142.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224734428.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224734731.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224734972.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224735197.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224735482.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224735809.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224736109.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224736455.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224736801.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224737151.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224737556.jpg
03/18/25
GRAPHIC
from 8-K g925335g0315224738399.jpg
03/18/25
GRAPHIC
from 8-K g925335g0316045733001.jpg
03/18/25
External Links